Author:
Shedrac Akor Egbunu,Haruna Musa,Gloria Eneojo-Abah Eleojo,Nma Yisa Benjamin,Titus Emmanuel Friday,Musa Dickson Achimugu,Oguche Joel Ikojo,Shaibu Serah,Tijani Salami,Bukbuk David,Abah Samuel Eneọjọ
Abstract
AbstractBackgroundSerum proteins designated as liver function biomarkers are used to evaluate patients for hepatic dysfunction. Hepatic effect of Anti-Retroviral Therapy (ART) needs further studies in HIV mono-infected patients. In this study, clinically defined patient datasets were analysed for protein levels in HIV-1 mono-infected seropositive patients with and without ART.Materials and MethodsData were collected for the study groups, consisting of the control group and HIV-1 mono-infected seropositive patients with and without ART and were analysed statistically for differences among the groups. All subjects in the patient groups attended University of Maiduguri Teaching Hospital, Nigeria for a period of 5 years.ResultThe protein levels on initiation of ART were significantly higher than baseline levels (prior to ART). However, continuous use of ART for 5-year period did not induce any further significant change in protein levels. Receiver Operating Characteristic (ROC) curves shows that both Albumin (ALB) and Total protein (TP) levels discriminated among the study groups. The baseline levels of ALB in seropositive patients are significantly lower to levels on initiation of ART.ConclusionContinuous ART did not cause any further significant change in levels of liver function proteins than was observed on ART initiation. Hence, liver damage on continuous ART is not implied. Both ALB and TP levels could be important in HIV management of patients. Initiation of ART appears to elevate the low ALB level via a yet unknown mechanism and indicates possible role of ALB in ART mechanism of action.
Publisher
Cold Spring Harbor Laboratory